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A transient COS-7 cell expression system was used to
investigate the functional domain arrangement of tissue
inhibitor of metalloproteinases-3 (TIMP-3), specifically
to assess the contribution of the amino- and carboxyl-
terminal domains of the molecule to its matrix metallo-
proteinase (MMP) inhibitory and extracellular matrix
(ECM) binding properties. Wild type TIMP-3 was en-
tirely localized to the ECM in both its glycosylated (27
kDa) and unglycosylated (24 kDa) forms. A COOH-termi-
nally truncated TIMP-3 molecule was found to be a non-
ECM bound MMP inhibitor, whereas a chimeric TIMP
molecule, consisting of the NH2-terminal domain of
TIMP-2 fused to the COOH-terminal domain of TIMP-3,
displayed ECM binding, albeit with a lower affinity than
the wild type TIMP-3 molecule. Thus the functional do-
main arrangement of TIMP-3 is analogous to that seen in
TIMP-1 and -2, namely that the NH2-terminal domain is
responsible for MMP inhibition whereas the COOH-ter-
minal domain is most important in mediating the spe-
cific functions of the molecule. A mutant TIMP-3 in
which serine 181 was changed to a cysteine, found in
Sorsby’s fundus dystrophy, a hereditary macular degen-
erative disease, was also expressed in COS-7 cells. This
gave rise to an additional 48-kDa species (possibly a
TIMP-3 dimer) that retained its ability to inhibit MMPs
and localize to the ECM. These data favor the hypothesis
that the TIMP-3 mutations seen in Sorsby’s fundus dys-
trophy contribute to disease progression by accumula-
tion of mutant protein rather than by the loss of func-
tional TIMP-3.
The matrix metalloproteinases (MMPs)1 are a family of zinc-
dependent endopeptidases that exist in both secreted and
membrane bound forms. The enzymes are initially expressed
as inactive pro-enzymes becoming activated by proteolytic
cleavage of their amino termini. The activity of MMPs is tightly
regulated by the tissue inhibitors of metalloproteinases
(TIMPs), a family of secreted proteins currently comprising
four members (TIMP-1–TIMP-4) (1–4). The balance between
MMPs and TIMPs regulates the integrity of the proteinacious
extracellular matrix (ECM) and thus plays a key role in a wide
range of physiological processes that include embryonic devel-
opment, connective tissue remodeling, wound healing, glandu-
lar morphogenesis, and angiogenesis. An imbalance in MMP/
TIMP expression has been implicated in various diseases such
as erosive joint disease, cardiovascular disease, and cancer
(reviewed in Refs. 5–7).
The TIMPs form high affinity 1:1 complexes with the active
forms of most MMPs (reviewed in Ref. 8) but show varying
specificity for different pro-MMPs allowing TIMPs to control
the activation of specific MMPs (9–12). Activities have also
been ascribed to the TIMPs that are independent of their abil-
ity to inhibit MMPs; for example, anti-angiogenic and eryth-
roid-potentiating activities have been described for TIMP-1
that are independent of MMP inhibition (13, 14). Likewise
TIMP-2 shows MMP independent inhibition of endothelial tube
formation (15). These differences in TIMP specificities, to-
gether with the finding that TIMPs are regulated differently at
the transcriptional level (reviewed in Refs. 16 and 17), have led
to the hypothesis that the individual family members have
specific physiological roles rather than being interchangeable
protease inhibitors.
The third member of the TIMP gene family, TIMP-3, is
unique because it is associated with the insoluble ECM (18).
TIMP-3 was originally identified as a molecule up-regulated in
viral transformation of chicken fibroblasts, a process in which
it acted as a growth factor in low serum conditions and tem-
pered the attachment of cells (19). Transcription of TIMP-3 has
been shown to be regulated by a wide variety of cytokines and
growth factors (18) and to be up-regulated during early G1
phase of cell cycle progression (20). Limited characterization of
human TIMP-3 has shown it to be an effective MMP inhibitor
in line with the other family members and to be produced in
both glycosylated and unglycosylated forms (21). Like TIMP-1
and -2, TIMP-3 has been show to have anti-angiogenic activity
(22). It has been reported that TIMP-1 and -2 consist of 2
functional domains, their NH2-terminal domains being respon-
sible for MMP inhibition and their COOH-terminal domains
performing their specific functions (23, 24). Structural studies
on these molecules have shown that their NH2-terminal do-
mains have very similar tertiary structures, both being mem-
bers of the oligonucleotide/oligosaccharide binding fold family
(25, 26). Amino acid sequence comparisons suggest that
TIMP-3 will have a similar functional domain arrangement
(27) and a similar tertiary structure to TIMP-1 and -2, enforced
by six disulfide bonds that have been shown to form in TIMP-1
(26, 28) and are assumed to form in the other TIMP family
members.
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Mutations to TIMP-3, all of which introduce an extra cys-
teine residue into exon 5 (which forms part of the COOH-
terminal domain of the molecule), have been linked to the
macular degenerative disease Sorsby’s fundus dystrophy (SFD)
(17, 29) in which patients typically lose central vision in middle
age (fourth or fifth decade) (30). SFD is an autosomal dominant
disorder characterized by abnormal deposits and thickening in
Bruch’s membrane, atrophy of the choriocapillaris, retinal pig-
ment epithelium and photoreceptors, and subretinal neovascu-
larization. The effects of the SFD mutations on TIMP-3 func-
tion are unknown. The aim of this study was to determine
whether TIMP-3 exhibits a similar functional domain structure
to that of TIMP-1 and -2 and to begin to investigate the effects
of SFD mutations on TIMP-3 function
EXPERIMENTAL PROCEDURES
Expression Plasmid Construction—Synthetic oligonucleotide prim-
ers were used to create expression constructs by standard polymerase
chain reaction-based techniques, in each case 59 EcoRI and 39 SalI sites
were introduced to allow cloning into the pCi.neo expression vector
(Promega UK). All polymerase chain reaction reactions were performed
using Pwo DNA polymerase (Boehringer Mannheim UK). Wild type
TIMP-3, including the proregion, was amplified from vector
pCDNATIMP-3 (a kind gift from Dr. M. Wick, University of Marburg,
Germany) by polymerase chain reaction. TIMP-3 in which Asn184 was
changed to Glu (N184Q) or Ser181 was changed to Cys (S181C) were
created by introducing the mutations into the 39 primer. Truncated
TIMP-2 (full-length TIMP-2 clone was a kind gift from Dr. D. Rowan,
University of Newcastle upon Tyne, UK), and TIMP-3 constructs
(DTIMP-2 and DTIMP-3) were amplified using 39 primers that con-
verted residues Cys127 and Cys122, respectively, into stop codons. The
TIMP-2-TIMP-3 chimera was created by overlap extension polymerase
chain reaction (31), such that the coding sequence for the proregion of
TIMP-2 and residues 1–126 of the mature protein were fused to resi-
dues 121–189 of TIMP-3. All constructs were cloned into pCI.neo ex-
pression vector by digestion with EcoRI and SalI restriction endonucle-
ases (Boehringer Mannheim UK) and ligation with T4 DNA ligase
(Promega UK). Plasmids for transfection were prepared with plasmid
midi or maxi kits (QIAGEN Ltd, UK). DNA sequences were confirmed
by sequencing on an Applied Biosystems automated DNA sequencer.
COS-7 Cell Transfection—COS-7 cells were routinely cultured in
Dulbecco’s modified Eagle’s medium 1 10% fetal calf serum in a 37 °C,
5% CO2 humidified incubator. Transfections were performed by DEAE-
dextran/dimethyl sulfoxide shock (32). 48 h after transfection the cells
were transferred to serum-free Dulbecco’s modified Eagle’s medium and
allowed to grow for a further 48 h. Cells, conditioned media and ECM
were then harvested according to Ref. 18. The majority of the condi-
tioned medium was then concentrated approximately 15-fold. The pro-
tein concentrations of the fractions were then determined using BCA
Protein Assay Reagent (Pierce & Warriner UK Ltd.), and equal protein
amounts were analyzed by protease/substrate SDS-polyacrylamide gel
electrophoresis.
Protease/Substrate SDS-Polyacrylamide Gel Electrophoresis (Re-
verse Zymography)—Samples were analyzed on 12 or 15% acrylamide
protease/substrate gels according to Ref. 33, except that phorbol myris-
tate acetate stimulated U937 cell-conditioned medium at a final con-
centration of 10% (v/v) was used as a source of gelatinase activity (34),
and gelatin was incorporated into the gel at a final concentration of 2.5
mg/ml. Following staining with Coomassie Brilliant Blue (Sigma Chem-
ical Co., UK), inhibitory species were visualized as dark blue bands
against a clear background.
Immunoblotting—Reduced or nonreduced (heated for 10 min at 95 °C
with or without 2% 2-mercaptoethanol, respectively) samples were sep-
arated on 10% SDS-polyacrylamide gel electrophoresis gels with bioti-
nylated molecular mass markers (Amersham International plc UK)
prior to blotting onto a polyvinylidene difluoride membrane (Pierce &
Warriner (UK) Ltd.) in 10 mM CAPS 1 10% methanol (pH 11.0) at 60
mA overnight. Membranes were blocked by incubation with Tris-buff-
ered saline, pH 7.5 1 3% bovine serum albumin 1 0.2% Tween 20 for
2 h. Rabbit anti-TIMP-3 antibody (Insight Biotechnology Ltd UK) was
diluted (1:500) in Tris-buffered saline 1 3% bovine serum albumin 1
0.05% Tween 20 (antibody dilution buffer) and incubated with the blots
for 2 h. Membranes were washed extensively in Tris-buffered saline and
Tris-buffered saline 1 0.1% Tween 20, prior to incubation with horse-
radish peroxidase-labeled secondary antibody (Sigma UK) (1:10,000)
and streptavidin-horseradish peroxidase conjugate (1:1, 500) (Amer-
sham International plc UK) in antibody dilution buffer for 30 min.
Membranes were then washed as before and developed with ECL rea-
gent (Amersham International plc UK).
RESULTS
Mock Transfected COS-7 Cells—No inhibitory species were
detected in reverse zymograms of ECM or unconcentrated con-
ditioned medium from the pCI.neo mock transfected COS-7
cells (Fig. 1, lane A, and Fig. 2, lane A). However 15-fold
concentration of the conditioned medium revealed the presence
of three inhibitors (Fig. 3, lane A): two major bands at approx-
imately 28 and 22 kDa (most likely TIMP-1 and TIMP-2, re-
spectively) and a minor, approximately 24-kDa species (possi-
bly partially degraded or deglycosylated TIMP-1 or trace
amounts of TIMP-3). No cross-reactivity was observed between
these fractions and the anti-TIMP-3 antibody in Western blot-
ting, whereas the anti-TIMP-2 antibody cross-reacted with an
approximately 22-kDa protein in the 15-fold concentrated con-
ditioned medium (data not shown).
Wild Type TIMP-3 Transfected COS-7 Cells—Reverse zymo-
grams of ECM from cells transfected with plasmid pCITIMP-3
revealed the presence of two inhibitory species: a major one at
approximately 24 kDa and a minor one at approximately 27
kDa (Fig. 1, lane B). These correspond to the previously re-
ported molecular masses of unglycosylated and glycosylated
TIMP-3, respectively (21), and are in agreement with the re-
sults of mouse TIMP-3 expression in COS-1 cells (18). The same
cells grown in the presence of 5 mg/ml tunicamycin expressed
only the 24-Da band (data not shown), indicating that the
27-kDa band is indeed an N-glycosylated variant of TIMP-3.
Western blotting with anti-TIMP-3 antibody only identified a
24-kDa protein in the ECM from these cells (data not shown),
and this may reflect a reduced affinity of this antibody for the
glycosylated form of TIMP-3. The conditioned medium from
these cells displayed the same pattern and levels of inhibitors
as the mock transfected cells. Thus recombinant human
TIMP-3 produced from COS-7 cells is localized solely to the
ECM.
N184Q-TIMP-3 Transfected COS-7 Cells—TIMP-3 has been
shown to be N-glycosylated (21). To determine whether glyco-
sylation affects ECM localization, COS-7 cells were transfected
with a TIMP-3 mutant in which the only potential N-glycosy-
lation site, Asn184, was changed to a Gln. These transfected
cells produced a single strong inhibitory species of approxi-
mately 24 kDa in their ECM (Fig. 1, lane C), corresponding to
the molecular mass of unglycosylated TIMP-3. This was con-
firmed by Western blotting with anti-TIMP-3 antibody. No
additional inhibitory species were detected in conditioned me-
dium from these cells.
DTIMP-3 Transfected COS-7 Cells—No additional inhibitory
species (relative to mock transfected cells) could be detected in
the ECM or unconcentrated conditioned medium of COS-7 cells
transfected with DTIMP-3, which lacks the COOH-terminal
domain (data not shown). 15-fold concentration of the condi-
FIG. 1. Reverse zymogram of ECM from transfected COS-7
cells. Lane A, mock transfected; lane B, wild type TIMP-3 transfected;
lane C, N184Q-TIMP-3 transfected; lane D, TIMP-2-TIMP-3 chimera
transfected. Positions of molecular mass markers are indicated on the
left.
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tioned medium, however, revealed the presence of a unique low
molecular mass inhibitory species of approximately 13 kDa
(Fig. 3, lane B), correlating well with the predicted size of
DTIMP-3 of 13.9 kDa. The amino-terminal domain of TIMP-3 is
therefore a soluble molecule and is sufficient for MMP
inhibition.
TIMP-2-TIMP-3 Chimera Transfected COS-7 Cells—This
molecule was constructed to determine whether the COOH-
terminal domain of TIMP-3 is sufficient for ECM localization.
The unconcentrated conditioned medium from these cells con-
tained two strongly stained inhibitory species with approxi-
mate molecular masses of 24 and 27 kDa (Fig. 2, lane B). These
correspond well to the predicted molecular masses of the un-
glycosylated and glycosylated chimeras, assuming that the gly-
cosylation of the chimera is analogous to that of wild type
TIMP-3 (no N-glycosylation sites are present in the amino-
terminal domain of TIMP-2). Culturing the same cells with 5
mg/ml tunicamycin led to the loss of the higher molecular mass
band (Fig. 2, lane C), confirming that this molecule is an
N-glycosylated MMP inhibitor. The ECM produced by these
cells contained increased levels of an approximately 24-kDa
inhibitory species, but the 27-kDa band was absent (Fig. 1, lane
D). Cells transfected with DTIMP-2, a TIMP-2 mutant trun-
cated at Glu126 but lacking the TIMP-3 COOH-terminal do-
main, produced no additional inhibitory species in their ECM
(relative to mock transfected cells) but had an additional in-
hibitory species of approximately 15 kDa in their conditioned
medium (data not shown), corresponding closely to the calcu-
lated molecular mass for DTIMP-2 of 14.1 kDa.
S181C-TIMP-3 Transfected Cells (SFD Mutation)—Uncon-
centrated and concentrated conditioned media from COS-7
cells transfected with the SFD mutant TIMP-3 in which Ser181
is changed to Cys contained no additional inhibitory species
relative to the mock transfected cells (data not shown). How-
ever, analysis of the ECM from these cells revealed the pres-
ence of small amounts of an inhibitory species at approximately
24 kDa and also a novel inhibitory species at approximately 48
kDa (Fig. 4). These molecular masses correspond to those of
unglycosylated TIMP-3 monomer and dimer, respectively.
Western blotting with the anti-TIMP-3 antibody confirmed
that both bands contained TIMP-3 (Fig. 5).
DISCUSSION
The data presented in this report confirm that TIMP-3 shows
an analogous functional domain structure to TIMP-1 and -2 in
which the NH2-terminal domain is responsible for MMP inhi-
bition and the COOH terminus confers the specific biochemical
properties of the molecule. Specifically we have shown that the
three NH2-terminal domains (comprising residues 1–121) are
sufficient for MMP inhibition, whereas the three COOH-termi-
nal domains (comprising residues 121–189) confer most of the
unique ability of the molecule to localize to the ECM. Wild type
TIMP-3 was solely localized to the ECM and was undetectable
in the conditioned medium, whereas the reverse was true for
DTIMP-3, lacking the three COOH-terminal domains. How-
ever, the TIMP-2-TIMP-3 chimera was found in both the ECM
and the conditioned medium. Replacement of the NH2-terminal
domains of TIMP-3 with those of TIMP-2 may partially inhibit
the ability of the COOH-terminal domain to bind to the ECM in
the normal way, or this may be indicative of a contribution of
the amino terminus of TIMP-3 to ECM localization. The latter
explanation is supported by the hypothesis that TIMP-3 binds
to the ECM component hyaluronate via regions of basic amino
acids (19), because both domains of TIMP-3 contain large num-
bers of positive charges that could contribute to such an inter-
action. Interestingly although both unglycosylated and glyco-
sylated forms of wild type TIMP-3 were only detectable in the
ECM, the glycosylated form of the TIMP-2-TIMP-3 chimera
was only seen in the conditioned medium, whereas the non-
glycosylated form was detected in both ECM and conditioned
medium. This indicates that the decreased affinity of the chi-
mera for the ECM is further reduced by glycosylation. This
would support the idea that basicity contributes to the ECM
localization of TIMP-3 as glycosylation might be expected to
counter such an electrostatic interaction. Tunicamycin treat-
ment of wild type TIMP-3 together with mutation of the poten-
tial N-glycosylation site, Asn184, confirm that glycosylation
does occur at this residue but that this is not essential for either
MMP inhibition or ECM localization.
The finding that mutations in the TIMP-3 gene are linked to
the hereditary macular degenerative disease SFD (29) implied
that TIMP-3 could play a unique role in the eye. The symptoms
of SFD could either be because of insufficiency of normal
TIMP-3 or a negative effect of the mutant molecule itself. By
FIG. 2. Reverse zymogram of conditioned media from trans-
fected COS-7 cells. Lane A, mock transfected; lane B, TIMP-2-TIMP-3
chimera transfected; lane C, TIMP-2-TIMP-3 chimera transfected and
tunicamycin-treated. Positions of molecular mass markers are indi-
cated on the left.
FIG. 3. Reverse zymogram of concentrated conditioned media
from transfected COS-7 cells. Lane A, mock transfected; lane B,
DTIMP-3 transfected. Positions of molecular mass markers are indi-
cated on the left.
FIG. 4. Reverse zymogram of ECM from S181C-TIMP-3 trans-
fected COS-7 cells. Lane A, mock transfected; lane B, S181C-TIMP-3
transfected. Positions of molecular mass markers are indicated on the
left.
FIG. 5. Western blots of ECM from S181C-TIMP-3 transfected
COS-7 cells probed with anti-TIMP-3 antibody. Lane A, reduced;
lane B, nonreduced. Positions of molecular mass markers are indicated
on the left.
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expressing the S181C mutant form of TIMP-3 (the most fre-
quently observed SFD mutation) in COS-7 cells, we hoped to
begin to address this problem. Our data show for the first time
that although expressed at lower concentrations than wild type
TIMP-3, the SFD mutant is functional with respect to both
ECM localization and MMP inhibition. Additionally the muta-
tion gives rise to a novel molecule approximately twice the size
of the wild type TIMP-3, which is lost upon reduction with
2-mercaptoethanol. The most likely explanation for this is that
the free cysteine residue present in this mutant (and also in all
other known SFD mutations) causes TIMP-3 to dimerize or
associate with another molecule of identical size.
These data tend to support the hypothesis that the SFD
phenotype is caused by the mutant TIMP-3 molecule rather
than haploinsufficiency. The haploinsufficiency model requires
that expression from the normal allele (as SFD is a dominant
disease) is incapable of compensating for the mutated one. The
facts that TIMP-3 has been shown to inhibit angiogenesis and
that neovascularization is one of the symptoms of the disease
have been used to argue in favor of this model (22). However,
subretinal neovascularization is not always observed in SFD
(35). Additionally it has been shown that night blindness in
SFD is significantly responsive to treatment with high doses of
vitamin A, suggesting that the disease may be at least partially
a result of nutrient starvation of the retinal pigment epithe-
lium (36). Such starvation may well be caused by thickening of
Bruch’s membrane or atrophy of the choriocapillaris, both of
which are observed in SFD and both of which may give rise to
neovascularization as a secondary event.
Although SFD is very rare, its clinical and histopathological
features are almost identical to those of the most severe or
“wet” form of age-related macular degeneration (AMD). AMD
has a later age of onset than SFD and is the most common
cause of blindness in the elderly of developed countries. Al-
though recent work (37) has shown that some of the milder or
“dry” forms of AMD are associated with mutations in the ATP-
binding cassette transporter retina (ABCR) gene, other gene
defects have yet to be identified. Interestingly, although AMD
is not associated with heritable mutations in TIMP-3, all
drusen (lipid-rich deposits) associated with Bruch’s membrane
in AMD eyes stain strongly with anti-TIMP-3 antibodies (17). If
the two diseases are indeed closely related this would tend to
suggest that it is an excess rather than insufficiency of TIMP-3
that gives rise to the SFD phenotype. One possibility is that the
high molecular mass TIMP-3 complex we have observed is less
prone to degradation than the wild type molecule and so grad-
ually accumulates in the eye. Because the molecule remains
functional this would imply that it is inhibition of ECM remod-
eling that gives rise to the SFD phenotype. It is tempting to
speculate that similar TIMP-3 complexes may give rise to the
symptoms of AMD. This could result from abnormal disulfide
bond formation or somatic mutation giving rise to a more
gradual TIMP-3 accumulation than in SFD. Interestingly a
high molecular mass TIMP-3 immunoreactive complex has
been previously reported in tissue taken from a 69-year-old
human eye (38). TIMP-3 accumulation could therefore be a
common phenomenon in old age that is exacerbated in SFD and
AMD.
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